SAN RAFAEL, Calif., Feb. 24, 2026
SAN RAFAEL, Calif., Feb. 24, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will participate in four upcoming investor conferences in March.
TD Cowen 46th Annual Health Care Conference (Boston, MA)
Leerink 2026 Global Healthcare Conference (Miami, FL)
Jefferies 2026 Biotech on the Bay Summit (Miami, FL)
Barclays 28th Annual Global Healthcare Conference (Miami, FL)
The fireside chats will be webcast live and can be accessed by visiting BioMarin's website at https://investors.biomarin.com/. A webcast replay will be available through the Company's website for a limited time following the conferences.
About BioMarin
BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with multiple commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com.
| Contacts: | |
| Investors | Media |
| Traci McCarty | Marni Kottle |
| BioMarin Pharmaceutical Inc. | BioMarin Pharmaceutical Inc. |
| (415) 455-7558 | (650) 374-2803 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-in-four-upcoming-investor-conferences-in-march-302695288.html
SOURCE BioMarin Pharmaceutical Inc.

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.